New insights into autoimmune liver diseases

Hepatology Research

Volumn 38, Issue 8, 2008, Pages 745-761

  Kumagi, Teru ^a   Alswat, Khalid ^a   Hirschfield, Gideon M ^a   Heathcote, Jenny ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Autoimmune hepatitis; Autoimmune liver disease; IgG4 associated sclerosing cholangitis; Primary biliary cirrhosis; Primary sclerosing cholangitis; Secondary sclerosing cholangitis

Indexed keywords

ANTINUCLEAR ANTIBODY; AZATHIOPRINE; BEZAFIBRATE; CD20 ANTIBODY; CYCLOSPORIN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA DR ANTIGEN; HLA DR3 ANTIGEN; HLA DR4 ANTIGEN; IMMUNOGLOBULIN G4; MERCAPTOPURINE; MITOCHONDRION ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NORURSODEOXYCHOLIC ACID; OXOGLUTARATE DEHYDROGENASE; PREDNISONE; PYRUVATE DEHYDROGENASE; SMOOTH MUSCLE ANTIBODY; TACROLIMUS; URSODEOXYCHOLIC ACID; URSODEOXYCHOLIC ACID DERIVATIVE;

AUTOIMMUNE HEPATITIS; BILE DUCT CARCINOMA; CANCER RISK; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG MEGADOSE; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENVIRONMENTAL FACTOR; FATIGUE; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNOGLOBULIN G4 ASSOCIATED SCLEROSING CHOLANGITIS; INCIDENCE; INTERMETHOD COMPARISON; LIVER BIOPSY; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; NEPHROTOXICITY; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; SCLEROSING CHOLANGITIS; UNSPECIFIED SIDE EFFECT;

EID: 47649095744     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2008.00366.x     Document Type: Review

References (200)

1. Heathcote EJ. Past, present and future of Hepatology. In: Diehl AM, Hayashi N, Manns MP, Sauerbruch T, eds. Falk Symposium 157: Chronic Hepatitis: Metabolic, Cholestatic, Viral and Autoimmune. Dordrecht, The Netherlands: Springer, 2007; 167-77.
2. Mackay IR, Weiden S, Hasker J. Autoimmune hepatitis. Ann N Y Acad Sci 1965; 124: 767-80.
3. Reuben A. A sheep in wolf's clothing. Hepatology 2003; 38: 1596-601.
4. Feld JJ, Dinh H, Arenovich T, Marcus VA, Wanless IR, Heathcote EJ. Autoimmune hepatitis: Effect of symptoms and cirrhosis on natural history and outcome. Hepatology 2005; 42: 53-62.
5. Alvarez F, Berg PA, Bianchi FB et al. International Autoimmune Hepatitis Group Report: Review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-38.
6. Krawitt EL. Autoimmune hepatitis. N Engl J Med 2006; 354(1): 54-66.
7. Strassburg CP, Manns MP. Autoantibodies and autoantigens in autoimmune hepatitis. Semin Liver Dis 2002; 22: 339-52.
8. Chapman RW, Arborgh BA, Rhodes JM et al. Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. Gut 1980; 21: 870-7.
9. Granito A, Muratori L, Muratori P et al. Antibodies to filamentous actin (F-actin) in type 1 autoimmune hepatitis. J Clin Pathol 2006; 59: 280-4.
10. Longhi MS, Hussain MJ, Bogdanos DP et al. Cytochrome P450IID6-specific CD8 T cell immune responses mirror disease activity in autoimmune hepatitis type 2. Hepatology 2007; 46: 472-84.
11. Homberg JC, Abuaf N, Bernard O et al. Chronic active hepatitis associated with anti-liver/kidney microsome antibody type 1: A second type of "autoimmune" hepatitis. Hepatology 1987; 7: 1333-9.
12. Marceau G, Lapierre P, Beland K, Soudeyns H, Alvarez F. LKM1 autoantibodies in chronic hepatitis C infection: A case of molecular mimicry? Hepatology 2005; 42: 675-82.
13. Kogure T, Ueno Y, Fukushima K et al. Fulminant hepatic failure in a case of autoimmune hepatitis in hepatitis C during peg-interferon-alpha 2b plus ribavirin treatment. World J Gastroenterol 2007; 13: 4394-7.
14. Lapierre P, Hajoui O, Homberg JC, Alvarez F. Formiminotransferase cyclodeaminase is an organ-specific autoantigen recognized by sera of patients with autoimmune hepatitis. Gastroenterology 1999; 116: 643-9.
15. Clemente MG, Meloni A, Obermayer-Straub P, Frau F, Manns MP, De Virgiliis S. Two cytochromes P450 are major hepatocellular autoantigens in autoimmune polyglandular syndrome type 1. Gastroenterology 1998; 114: 324-8.
16. Herkel J, Manns MP, Lohse AW. Selenocysteine, soluble liver antigen/ liver-pancreas, and autoimmune hepatitis. Hepatology 2007; 46: 275-7.
17. Lu F, Xia Q, Ma Y et al. Serum proteomic-based analysis for the identification of a potential serological marker for autoimmune hepatitis. Biochem Biophys Res Commun 2008; 367: 284-90.
18. Boberg KM. Prevalence and epidemiology of autoimmune hepatitis. Clin Liver Dis 2002; 6: 635-47.
19. Czaja AJ, Carpenter HA. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology 2006; 43: 532-8.
20. Leung PS, Rossaro L, Davis PA et al. Antimitochondrial antibodies in acute liver failure: Implications for primary biliary cirrhosis. Hepatology 2007; 46: 1436-42.
21. Czaja AJ, Bianchi FB, Carpenter HA et al. Treatment challenges and investigational opportunities in autoimmune hepatitis. Hepatology 2005; 41: 207-15.
22. Manns MP, Vogel A. Autoimmune hepatitis, from mechanisms to therapy. Hepatology 2006; 43(Suppl. 1): S132-44.
23. Liu ZX, Kaplowitz N. Immune-mediated drug-induced liver disease. Clin Liver Dis 2002; 6: 755-74.
24. Stricker BH, Blok AP, Claas FH, Van Parys GE, Desmet VJ. Hepatic injury associated with the use of nitrofurans: A clinicopathological study of 52 reported cases. Hepatology 1988; 8: 599-606.
25. Mieli-Vergani G, Vergani D. De novo autoimmune hepatitis after liver transplantation. J Hepatol 2004; 40: 3-7.
26. Aguilera I, Sousa JM, Gavilan F, Bernardos A, Wichmann I, Nunez-Roldan A. Glutathione S-transferase T1 mismatch constitutes a risk factor for de novo immune hepatitis after liver transplantation. Liver Transpl 2004; 10: 1166-72.
27. Christen U, Holdener M, Hintermann E. Animal models for autoimmune hepatitis. Autoimmun Rev 2007; 6: 306-11.
28. Djilali-Saiah I, Lapierre P, Vittozi S, Alvarez F. DNA vaccination breaks tolerance for a neo-self antigen in liver: A transgenic murine model of autoimmune hepatitis. J Immunol 2002; 169: 4889-96.
29. Lapierre P, Djilali-Saiah I, Vitozzi S, Alvarez F. A murine model of type 2 autoimmune hepatitis: Xenoimmunization with human antigens. Hepatology 2004; 39: 1066-74.
30. Lapierre P, Beland K, Alvarez F. Pathogenesis of autoimmune hepatitis: from break of tolerance to immune-mediated hepatocyte apoptosis. Transl Res 2007; 149(3): 107-13.
31. Longhi MS, Hussain MJ, Mitry RR et al. Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis. J Immunol 2006; 176: 4484-91.
32. Summerskill WH. Chronic active liver disease reexamined: Prognosis hopeful. Gastroenterology 1974; 66: 450-64.
33. Montano Loza AJ, Czaja AJ. Current therapy for autoimmune hepatitis. Nat Clin Pract Gastroenterol Hepatol 2007; 4: 202-14.
34. De Groote J, Fevery J, Lepoutre L. Long-term follow-up of chronic active hepatitis of moderate severity. Gut 1978; 19: 510-13.
35. Heathcote J. Treatment strategies for autoimmune hepatitis. Am J Gastroenterol 2006; 101(Suppl. 12): S630-2.
36. Kogan J, Safadi R, Ashur Y, Shouval D, Ilan Y. Prognosis of symptomatic versus asymptomatic autoimmune hepatitis: A study of 68 patients. J Clin Gastroenterol 2002; 35: 75-81.
37. Ferrari R, Pappas G, Agostinelli D et al. Type 1 autoimmune hepatitis: patterns of clinical presentation and differential diagnosis of the "acute" type. Qjm 2004; 97: 407-12.
38. Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 1995; 333: 958-63.
39. Inductivo-Yu I, Adams A, Gish RG et al. Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy. Clin Gastroenterol Hepatol 2007; 5: 799-802.
40. Richardson PD, James PD, Ryder SD. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol 2000; 33: 371-5.
41. Geier A, Gartung C, Dietrich CG, Wasmuth HE, Reinartz P, Matern S. Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: Influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC. World J Gastroenterol 2003; 9: 2681-5.
42. Aqel BA, Machicao V, Rosser B, Satyanarayana R, Harnois DM, Dickson RC. Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J Clin Gastroenterol 2004; 38: 805-9.
43. Kerkar N, Dugan C, Rumbo C et al. Rapamycin successfully treats post-transplant autoimmune hepatitis. Am J Transplant 2005; 5: 1085-9.
44. Santos ES, Arosemena LR, Raez LE, O'Brien C, Regev A. Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: Case report and review of literature. Liver Int 2006; 26: 625-9.
45. Ozorio G, McGarity B, Bak H, Jordan AS, Lau H, Marshall C. Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis. Med J Aust 2007; 5: 187: 524-6.
46. Werner M, Bjornsson E, Prytz H et al. Autoimmune hepatitis among fertile women: Strategies during pregnancy and breastfeeding? Scand J Gastroenterol 2007; 42: 986-91.
47. Heneghan MA, Norris SM, O'Grady JG, Harrison PM, McFarlane IG. Management and outcome of pregnancy in autoimmune hepatitis. Gut 2001; 48: 97-102.
48. Ichai P, Duclos-Vallee JC, Guettier C et al. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl 2007; 13: 996-1003.
49. Verma S, Gunuwan B, Mendler M, Govindrajan S, Redeker A. Factors predicting relapse and poor outcome in type I autoimmune hepatitis: Role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am J Gastroenterol 2004; 99: 1510-16.
50. Montano-Loza AJ, Carpenter HA, Czaja AJ. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease. Hepatology 2007; 46: 1138-45.
51. Montano-Loza AJ, Carpenter HA, Czaja AJ. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am J Gastroenterol 2007; 102: 1005-12.
52. Czaja AJ, Carpenter HA. Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis. Liver Int 2003; 23: 116-23.
53. Donaldson PT. Genetics of liver disease: Immunogenetics and disease pathogenesis. Gut 2004; 53: 599-608.
54. Czaja AJ. Current concepts in autoimmune hepatitis. Ann Hepatol 2005; 4: 6-24.
55. Strettell MD, Donaldson PT, Thomson LJ et al. Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. Gastroenterology 1997; 112: 2028-35.
56. Czaja AJ, Strettell MD, Thomson LJ et al. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Hepatology 1997; 25: 317-23.
57. Al-Chalabi T, Underhill JA, Portmann BC, McFarlane IG, Heneghan MA. Impact of gender on the long-term outcome and survival of patients with autoimmune hepatitis. J Hepatol 2008; 48: 140-7.
58. Verma S, Torbenson M, Thuluvath PJ. The impact of ethnicity on the natural history of autoimmune hepatitis. Hepatology 2007; 46: 1828-35.
59. Hurlburt KJ, McMahon BJ, Deubner H, Hsu-Trawinski B, Williams JL, Kowdley KV. Prevalence of autoimmune liver disease in Alaska Natives. Am J Gastroenterol 2002; 97: 2402-7.
60. Seki T, Ota M, Furuta S et al. HLA class II molecules and autoimmune hepatitis susceptibility in Japanese patients. Gastroenterology 1992; 103: 1041-7.
61. Miyake Y, Iwasaki Y, Takaki A et al. Human leukocyte antigen DR status and clinical features in Japanese patients with type 1 autoimmune hepatitis. Hepatol Res 2008; 38: 96-102.
62. Nakamura K, Yoneda M, Yokohama S et al. Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. J Gastroenterol Hepatol 1998; 13: 490-5.
63. Agarwal K, Czaja AJ, Jones DE, Donaldson PT. Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis. Hepatology 2000; 31: 49-53.
64. Yoshida EM, Riley M, Arbour LT. Autoimmune liver disease and the Canadian First Nations Aboriginal Communities of British Columbia's Pacific Northwest. World J Gastroenterol 2006; 12: 3625-7.
65. Yokosawa S, Yoshizawa K, Ota M et al. A genome-wide DNA microsatellite association study of Japanese patients with autoimmune hepatitis type 1. Hepatology 2007; 45: 384-90.
66. Kremer M, Perry AW, Milton RJ, Rippe RA, Wheeler MD, Hines IN. Pivotal role of Smad3 in a mouse model of T cell-mediated hepatitis. Hepatology 2008; 47: 113-26.
67. Agarwal K, Czaja AJ, Donaldson PT. A functional Fas promoter polymorphism is associated with a severe phenotype in type 1 autoimmune hepatitis characterized by early development of cirrhosis. Tissue Antigens 2007; 69: 227-35.
68. Sherlock S, Scheuer PJ. The presentation and diagnosis of 100 patients with primary biliary cirrhosis. N Engl J Med 1973; 289: 674-8.
69. Pla X, Vergara M, Gil M et al. Incidence, prevalence and clinical course of primary biliary cirrhosis in a Spanish community. Eur J Gastroenterol Hepatol 2007; 19: 859-64.
70. Addison T, Gull W. On a certain affliction of the skin - vitiligoides - a planus tuberosa. Guys Hospital Rev 1857; 7: 268.
71. Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med 2005; 353: 1261-73.
72. Jones DE. Pathogenesis of primary biliary cirrhosis. Gut 2007; 56: 1615-24.
73. Jung Y, McCall SJ, Li YX, Diehl AM. Bile ductules and stromal cells express hedgehog ligands and/or hedgehog target genes in primary biliary cirrhosis. Hepatology 2007; 45: 1091-6.
74. Robertson H, Kirby JA, Yip WW. Jones DE, Burt AD. Biliary epithelial-mesenchymal transition in post-transplantation recurrence of primary biliary cirrhosis. Hepatology 2007; 45: 977-81.
75. Prince MI, Chetwynd A, Craig WL, Metcalf JV, James OF. Asymptomatic primary biliary cirrhosis: Clinical features, prognosis, and symptom progression in a large population-based cohort. Gut 2004; 53: 865-70.
76. Vleggaar FP, van Buuren HR, Zondervan PE, ten Kate FJ, Hop WC. Jaundice in non-cirrhotic primary biliary cirrhosis: The premature ductopenic variant. Gut 2001; 49: 276-81.
77. Springer J, Cauch-Dudek K, O'Rourke K, Wanless IR, Heathcote EJ. Asymptomatic primary biliary cirrhosis: A study of its natural history and prognosis. Am J Gastroenterol 1999; 94: 47-53.
78. Corpechot C, Carrat F, Poupon R, Poupon RE. Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients. Gastroenterology 2002; 122: 652-8.
79. Nakamura M, Kondo H, Mori T et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 2007; 45: 118-27.
80. Murata Y, Abe M, Furukawa S et al. Clinical features of symptomatic primary biliary cirrhosis initially complicated with esophageal varices. J Gastroenterol 2006; 41: 1220-6.
81. Bogdanos DP, Liaskos C, Pares A et al. Anti-gp210 antibody mirrors disease severity in primary biliary cirrhosis. Hepatology 2007; 45: 1583; author reply -4.
82. Onishi S, Sakamaki T, Maeda T et al. DNA typing of HLA class II genes; DRB1 *0803 increases the susceptibility of Japanese to primary biliary cirrhosis. J Hepatol 1994; 21: 1053-60.
83. Selmi C, Gershwin ME, Lindor KD et al. Quality of life and everyday activities in patients with primary biliary cirrhosis. Hepatology 2007; 20: 46: -1836-43.
84. Newton JL, Gibson GJ, Tomlinson M, Wilton K, Jones D. Fatigue in primary biliary cirrhosis is associated with excessive daytime somnolence. Hepatology 2006; 44: 91-8.
85. Newton JL, Hudson M, Tachtatzis P et al. Population prevalence and symptom associations of autonomic dysfunction in primary biliary cirrhosis. Hepatology 2007; 45: 1496-505.
86. Jones DE, Bhala N, Burt J, Goldblatt J, Prince M, Newton JL. Four year follow up of fatigue in a geographically defined primary biliary cirrhosis patient cohort. Gut 2006; 55: 536-41.
87. Sakauchi F, Mori M, Zeniya M, Toda G. A cross-sectional study of primary biliary cirrhosis in Japan: Utilization of clinical data when patients applied to receive public financial aid. J Epidemiol 2005; 15: 24-8.
88. Sakauchi F, Oura A, Ohnishi H, Mori M. Comparison of the clinical features of Japanese patients with primary biliary cirrhosis in 1999 and 2004: Utilization of clinical data when patients applied to receive public financial aid. J Epidemiol 2007; 17: 210-14.
89. Heathcote EJ. Diagnosis and management of cholestatic liver disease. Clin Gastroenterol Hepatol 2007; 5: 776-82.
90. Lindor K. Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. N Engl J Med 2007; 357: 1524-9.
91. Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997; 113: 884-90.
92. Jackson H, Solaymani-Dodaran M, Card TR, Aithal GP, Logan R, West J. Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: A population-based cohort study. Hepatology 2007; 46: 1131-7.
93. Lee J, Belanger A, Doucette JT, Stanca C, Friedman S, Bach N. Transplantation trends in primary biliary cirrhosis. Clin Gastroenterol Hepatol 2007; 5: 1313-15.
94. Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 2006; 130: 715-20.
95. Rautiainen H, Karkkainen P, Karvonen AL et al. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: A three-year randomized trial. Hepatology 2005; 41: 747-52.
96. Ohmoto K, Yoshioka N, Yamamoto S. Long-term effect of bezafibrate on parameters of hepatic fibrosis in primary biliary cirrhosis. J Gastroenterol 2006; 41: 502-3.
97. Fiorucci S, Rizzo G, Donini A, Distrutti E, Santucci L. Targeting farnesoid X receptor for liver and metabolic disorders. Trends Mol Med 2007; 13: 298-309.
98. Combes B. Reflections on therapeutic trials in primary biliary cirrhosis. Hepatology 2005; 42: 1009.
99. Krasner N, Johnson PJ, Portmann B, Watkinson G, Macsween RN, Williams R. Hepatocellular carcinoma in primary biliary cirrhosis: Report of four cases. Gut 1979; 20: 255-8.
100. Jones DE, Metcalf JV, Collier JD, Bassendine MF, James OF. Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes. Hepatology 1997; 26: 1138-42.
101. Shibuya A, Tanaka K, Miyakawa H et al. Hepatocellular carcinoma and survival in patients with primary biliary cirrhosis. Hepatology 2002; 35: 1172-8.
102. Walker JG, Doniach D, Roitt IM, Sherlock S. Serological Tests in Diagnosis of Primary Biliary Cirrhosis. Lancet 1965; 17: 827-31.
103. Coppel RL, McNeilage LJ, Surh CD et al. Primary structure of the human M2 mitochondrial autoantigen of primary biliary cirrhosis: dihydrolipoamide acetyltransferase. Proc Natl Acad Sci USA 1988; 85: 7317-21.
104. Moteki S, Leung PS, Coppel RL et al. Use of a designer triple expression hybrid clone for three different lipoyl domain for the detection of antimitochondrial autoantibodies. Hepatology 1996; 24: 97-103.
105. Oertelt S, Rieger R, Selmi C et al. A sensitive bead assay for antimitochondrial antibodies: Chipping away at AMA-negative primary biliary cirrhosis. Hepatology 2007; 45: 659-65.
106. Gershwin ME, Mackay IR. The causes of primary biliary cirrhosis: convenient and inconvenient truths. Hepatology 2008; 47: 737-45.
107. Mattalia A, Quaranta S, Leung PS et al. Characterization of antimitochondrial antibodies in health adults. Hepatology 1998; 27: 656-61.
108. Nezu S, Tanaka A, Yasui H et al. Presence of antimitochondrial autoantibodies in patients with autoimmune hepatitis. J Gastroenterol Hepatol 2006; 21: 1448-54.
109. Liaskos C, Bogdanos DP, Rigopoulou EI, Dalekos GN. Development of antimitochondrial antibodies in patients with autoimmune hepatitis: Art of facts or an artifact? J Gastroenterol Hepatol 2007; 22: 454-5.
110. Donaldson PT, Baragiotta A, Heneghan MA et al. HLA class II alleles, genotypes, haplotypes and amino acids in primary biliary cirrhosis: A large-scale study. Hepatology 2006; 44: 667-74.
111. Irie J, Wu Y, Wicker LS et al. NOD.c3c4 congenic mice develop autoimmune biliary disease that serologically and pathogenetically models human primary biliary cirrhosis. J Exp Med 2006; 203: 1209-19.
112. Wakabayashi K, Lian ZX, Moritoki Y et al. IL-2 receptor alpha (-/-) mice and the development of primary biliary cirrhosis. Hepatology 2006; 44: 1240-9.
113. Mason AL. An autoimmune biliary disease mouse model for primary biliary cirrhosis: Something for everyone. Hepatology 2006; 44: 1047-50.
114. Chuang YH, Lian ZX, Yang GX et al. Natural killer T cells exacerbate liver injury in a transforming growth factor beta receptor II dominant-negative mouse model of primary biliary cirrhosis. Hepatology 2008; 47: 571-80.
115. Odin JA, Huebert RC, Casciola-Rosen L, LaRusso NF, Rosen A. Bcl-2-dependent oxidation of pyruvate dehydrogenase-E2, a primary biliary cirrhosis autoantigen, during apoptosis. J Clin Invest 2001; 108: 223-32.
116. Alabraba EB, Lai V, Boon L, Wigmore SJ, Adams DH, Afford SC. Coculture of human liver macrophages and cholangiocytes leads to CD40-dependent apoptosis and cytokine secretion. Hepatology 2008; 47: 552-62.
117. Watt FE, James OF, Jones DE. Patterns of autoimmunity in primary biliary cirrhosis patients and their families: A population-based cohort study. Qjm 2004; 97: 397-406.
118. Lan RY, Cheng C, Lian ZX et al. Liver-targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis. Hepatology 2006; 43: 729-37.
119. Lazaridis KN, Juran BD, Boe GM et al. Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis. Hepatology 2007; 46: 785-92.
120. Invernizzi P, Miozzo M, Battezzati PM et al. Frequency of monosomy X in women with primary biliary cirrhosis. Lancet 2004; 363(9408): 533-5.
121. Miozzo M, Selmi C, Gentilin B et al. Preferential X chromosome loss but random inactivation characterize primary biliary cirrhosis. Hepatology 2007; 46: 456-62.
122. Abdalian R, Heathcote EJ. Sclerosing cholangitis: A focus on secondary causes. Hepatology 2006; 44: 1063-74.
123. LaRusso NF, Shneider BL, Black D et al. Primary sclerosing cholangitis: summary of a workshop. Hepatology 2006; 44: 746-64.
124. Bergquist A, Said K, Broome U. Changes over a 20-year period in the clinical presentation of primary sclerosing cholangitis in Sweden. Scand J Gastroenterol 2007; 42: 88-93.
125. Bergquist A, Glaumann H, Lindberg B, Broome U. Primary sclerosing cholangitis can present with acute liver failure: Report of two cases. J Hepatol 2006; 44: 1005-8.
126. Broome U, Bergquist A. Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer. Semin Liver Dis 2006; 26: 31-41.
127. Berstad AE, Aabakken L, Smith HJ, Aasen S, Boberg KM, Schrumpf E. Diagnostic accuracy of magnetic resonance and endoscopic retrograde cholangiography in primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2006; 4: 514-20.
128. Meagher S, Yusoff I, Kennedy W, Martel M, Adam V, Barkun A. The roles of magnetic resonance and endoscopic retrograde cholangiopancreatography (MRCP and ERCP) in the diagnosis of patients with suspected sclerosing cholangitis: A cost-effectiveness analysis. Endoscopy 2007; 39: 222-8.
129. Elsayes KM, Oliveira EP, Narra VR et al. MR and MRCP in the evaluation of primary sclerosing cholangitis: Current applications and imaging findings. J Comput Assist Tomogr 2006; 30: 398-404.
130. Gregorio GV, Portmann B, Karani J et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: A 16-year prospective study. Hepatology 2001; 33: 544-53.
131. MacFaul GR, Chapman RW. Sclerosing cholangitis. Curr Opin Gastroenterol 2006; 22: 288-93.
132. Grant AJ, Lalor PF, Salmi M, Jalkanen S, Adams DH. Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease. Lancet 2002; 359(9301): 150-7.
133. Gaudio E, Franchitto A, Pannarale L et al. Cholangiocytes and blood supply. World J Gastroenterol 2006; 12: 3546-52.
134. Fickert P, Moustafa T, Trauner M. Primary sclerosing cholangitis - the arteriosclerosis of the bile duct? Lipids Health Dis 2007; 6: 3.
135. Karlsen TH, Schrumpf E, Boberg KM. Genetic epidemiology of primary sclerosing cholangitis. World J Gastroenterol 2007; 13: 5421-31.
136. Karlsen TH, Hampe J, Wiencke K et al. Genetic polymorphisms associated with inflammatory bowel disease do not confer risk for primary sclerosing cholangitis. Am J Gastroenterol 2007; 102: 115-21.
137. Pall H, Zielenski J, Jonas MM et al. Primary sclerosing cholangitis in childhood is associated with abnormalities in cystic fibrosis-mediated chloride channel function. J Pediatr 2007; 151: 255-9.
138. Gallegos-Orozco JF, Yurk CE, Wang N et al. Lack of association of common cystic fibrosis transmembrane conductance regulator gene mutations with primary sclerosing cholangitis. Am J Gastroenterol 2005; 100: 874-8.
139. Sheth S, Shea JC, Bishop MD et al. Increased prevalence of CFTR mutations and variants and decreased chloride secretion in primary sclerosing cholangitis. Hum Genet 2003; 113: 286-92.
140. Fickert P, Fuchsbichler A, Wagner M et al. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 2004; 127: 261-74.
141. Fickert P, Stoger U, Fuchsbichler A et al. A new xenobiotic-induced mouse model of sclerosing cholangitis and biliary fibrosis. Am J Pathol 2007; 171: 525-36.
142. Broome U, Olsson R, Loof L et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996; 38: 610-15.
143. Wiesner RH, Grambsch PM, Dickson ER et al. Primary sclerosing cholangitis: Natural history, prognostic factors and survival analysis. Hepatology 1989; 10: 430-6.
144. Tischendorf JJ, Hecker H, Kruger M, Manns MP, Meier PN. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: A single center study. Am J Gastroenterol 2007; 102: 107-14.
145. Ponsioen CY, Vrouenraets SM, Prawirodirdjo W et al. Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population. Gut 2002; 51: 562-6.
146. Levy C, Lindor KD. Primary sclerosing cholangitis: Epidemiology, natural history, and prognosis. Semin Liver Dis 2006; 26: 22-30.
147. Bjornsson E, Boberg KM, Cullen S et al. Patients with small duct primary sclerosing cholangitis have a favourable long-term prognosis. Gut 2002; 51: 731-5.
148. Angulo P, Maor-Kendler Y, Lindor KD. Small-duct primary sclerosing cholangitis: A long-term follow-up study. Hepatology 2002; 35: 1494-500.
149. Kim WR, Therneau TM, Wiesner RH et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc 2000; 75: 688-94.
150. Craig DA, MacCarty RL, Wiesner RH, Grambsch PM, LaRusso NF. Primary sclerosing cholangitis: Value of cholangiography in determining the prognosis. AJR Am J Roentgenol 1991; 157: 959-64.
151. Olsson RG, Asztely MS. Prognostic value of cholangiography in primary sclerosing cholangitis. Eur J Gastroenterol Hepatol 1995; 7: 251-4.
152. Petrovic BD, Nikolaidis P, Hammond NA et al. Correlation between findings on MRCP and gadolinium-enhanced MR of the liver and a survival model for primary sclerosing cholangitis. Dig Dis Sci 2007; 52: 3499-506.
153. Harnois DM, Angulo P, Jorgensen RA, Larusso NF, Lindor KD. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol 2001; 96: 1558-62.
154. Olsson R, Boberg KM, de Muckadell OS et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: A 5-year multicenter, randomized, controlled study. Gastroenterology 2005; 129: 1464-72.
155. Pardi DS, Loftus EV Jr, Kremers WK, Keach J, Lindor KD. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003; 124: 889-93.
156. Rudolph G, Kloeters-Plachky P, Rost D, Stiehl A. The incidence of cholangiocarcinoma in primary sclerosing cholangitis after long-time treatment with ursodeoxycholic acid. Eur J Gastroenterol Hepatol 2007; 19: 487-91.
157. Fickert P, Wagner M, Marschall HU et al. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 2006; 130: 465-81.
158. Talwalkar JA, Angulo P, Keach JC, Petz JL, Jorgensen RA, Lindor KD. Mycophenolate mofetil for the treatment of primary sclerosing cholangitis. Am J Gastroenterol 2005; 100: 308-12.
159. Talwalkar JA, Gossard AA, Keach JC, Jorgensen RA, Petz JL, Lindor RN. Tacrolimus for the treatment of primary sclerosing cholangitis. Liver Int 2007; 27: 451-3.
160. Kita R, Takamatsu S, Kimura T, Kokuryu H, Osaki Y, Tomono N. Bezafibrate may attenuate biliary damage associated with chronic liver diseases accompanied by high serum biliary enzyme levels. J Gastroenterol 2006; 41: 686-92.
161. Bjoro K, Brandsaeter B, Foss A, Schrumpf E. Liver transplantation in primary sclerosing cholangitis. Semin Liver Dis 2006; 26: 69-79.
162. Haga H, Miyagawa-Hayashino A, Taira K et al. Histological recurrence of autoimmune liver diseases after living-donor liver transplantation. Hepatol Res 2007; 37(Suppl. 3): S463-9.
163. Gordon F. Recurrent primary sclerosing cholangitis. Clinical diagnosis and long-term management issues. Liver Transpl 2006; 12(Suppl. 2): S73-5.
164. Maggs JR, Chapman RW. Sclerosing cholangitis. Curr Opin Gastroenterol 2007; 23: 310-16.
165. Gossard AA, Angulo P, Lindor KD. Secondary sclerosing cholangitis: A comparison to primary sclerosing cholangitis. Am J Gastroenterol 2005; 100: 1330-3.
166. Tenner S, Roston A, Lichtenstein D, Brooks D, Herlihy E, Carr-Locke D. Eosinophilic cholangiopathy. Gastrointest Endosc 1997; 45: 307-9.
167. Kawa S, Hamano H, Umemura T, Kiyosawa K, Uehara T. Sclerosing cholangitis associated with autoimmune pancreatitis. Hepatol Res 2007; 37(Suppl. 3): S487-95.
168. Kamisawa T, Funata N, Hayashi Y et al. A new clinicopathological entity of IgG4-related autoimmune disease. J Gastroenterol 2003; 38: 982-4.
169. Deheragoda MG, Church NI, Rodriguez-Justo M et al. The use of immunoglobulin g4 immunostaining in diagnosing pancreatic and extrapancreatic involvement in autoimmune pancreatitis. Clin Gastroenterol Hepatol 2007; 5: 1229-34.
170. Kamisawa T, Funata N, Hayashi Y et al. Close relationship between autoimmune pancreatitis and multifocal fibrosclerosis. Gut 2003; 52: 683-7.
171. Bjornsson E, Chari ST, Smyrk TC, Lindor K. Immunoglobulin G4-associated cholangitis: Description of an emerging clinical entity based on review of the literature. Hepatology 2007; 45: 1547-54.
172. Umemura T, Zen Y, Hamano H, Kawa S, Nakanuma Y, Kiyosawa K. Immunoglobin G4-hepatopathy: Association of immunoglobin G4-bearing plasma cells in liver with autoimmune pancreatitis. Hepatology 2007; 46: 463-71.
173. Kim MH, Kwon S. Diagnostic criteria for autoimmune chronic pancreatitis. J Gastroenterol 2007; 42(Suppl. 18): 42-9.
174. Chari ST. Diagnosis of autoimmune pancreatitis using its five cardinal features: Introducing the Mayo Clinic's HISORt criteria. J Gastroenterol 2007; 42(Suppl. 18): 39-41.
175. Nakazawa T, Ohara H, Sano H et al. Clinical differences between primary sclerosing cholangitis and sclerosing cholangitis with autoimmune pancreatitis. Pancreas 2005; 30: 20-5.
176. Nishino T, Toki F, Oyama H, Shimizu K, Shiratori K. Long-term outcome of autoimmune pancreatitis after oral prednisolone therapy. Intern Med 2006; 45: 497-501.
177. Mendes FD, Jorgensen R, Keach J et al. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol 2006; 101: 2070-5.
178. Hamano H, Kawa S, Uehara T et al. Immunoglobulin G4-related lymphoplasmacytic sclerosing cholangitis that mimics infiltrating hilar cholangiocarcinoma: Part of a spectrum of autoimmune pancreatitis? Gastrointest Endosc 2005; 62: 152-7.
179. Ito T, Nishimori I, Inoue N et al. Treatment for autoimmune pancreatitis: Consensus on the treatment for patients with autoimmune pancreatitis in Japan. J Gastroenterol 2007; 42(Suppl. 18): 50-8.
180. Church NI, Pereira SP, Deheragoda MG et al. Autoimmune pancreatitis: clinical and radiological features and objective response to steroid therapy in a UK series. Am J Gastroenterol 2007; 102: 2417-25.
181. Hirano K, Tada M, Isayama H et al. Long-term prognosis of autoimmune pancreatitis with and without corticosteroid treatment. Gut 2007; 56: 1719-24.
182. Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: A meta-analysis. Gastrointest Endosc 2002; 56: 48-54.
183. Jess T, Loftus EV Jr, Velayos FS et al. Risk factors for colorectal neoplasia in inflammatory bowel disease: A nested case-control study from Copenhagen county, Denmark and Olmsted county, Minnesota. Am J Gastroenterol 2007; 102: 829-36.
184. Bergquist A, Ekbom A, Olsson R et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002; 36: 321-7.
185. Kaplan GG, Heitman SJ, Hilsden RJ et al. Population-based analysis of practices and costs of surveillance for colonic dysplasia in patients with primary sclerosing cholangitis and colitis. Inflamm Bowel Dis 2007; 13: 1401-7.
186. Burak K, Angulo P, Pasha TM, Egan K, Petz J, Lindor KD. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 2004; 99: 523-6.
187. Lazaridis KN, Gores GJ. Primary sclerosing cholangitis and cholangiocarcinoma. Semin Liver Dis 2006; 26: 42-51.
188. Boberg KM, Bergquist A, Mitchell S et al. Cholangiocarcinoma in primary sclerosing cholangitis: Risk factors and clinical presentation. Scand J Gastroenterol 2002; 37: 1205-11.
189. Melum E, Karlsen TH, Schrumpf E et al. Cholangiocarcinoma in primary sclerosing cholangitis is associated with NKG2D polymorphisms. Hepatology 2008; 47: 90-6.
190. Malhi H, Gores GJ. Cholangiocarcinoma: Modern advances in understanding a deadly old disease. J Hepatol 2006; 45: 856-67.
191. Gores GJ, Nagorney DM, Rosen CB. Cholangiocarcinoma: Is transplantation an option? For whom? J Hepatol 2007; 47: 455-9.
192. Beuers U, Rust C. Overlap syndromes. Semin Liver Dis 2005; 25: 311-20.
193. Czaja AJ, Carpenter HA. Autoimmune hepatitis with incidental histologic features of bile duct injury. Hepatology 2001; 34(Pt 1): 659-65.
194. Abdalian R, Dhar P, Jhaveri K, Haider M, Guindi M, Heathcote EJ. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: Evaluating the role of routine magnetic resonance imaging. Hepatology 2008; 47: 949-57.
195. Boberg KM, Fausa O, Haaland T et al. Features of autoimmune hepatitis in primary sclerosing cholangitis: An evaluation of 114 primary sclerosing cholangitis patients according to a scoring system for the diagnosis of autoimmune hepatitis. Hepatology 1996; 23: 1369-76.
196. Poupon R, Chazouilleres O, Corpechot C, Chretien Y. Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis. Hepatology 2006; 44: 85-90.
197. Czaja AJ. Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology 1998; 28: 360-5.
198. Chazouilleres O, Wendum D, Serfaty L, Montembault S, Rosmorduc O, Poupon R. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998; 28: 296-301.
199. Silveira MG, Talwalkar JA, Angulo P, Lindor KD. Overlap of autoimmune hepatitis and primary biliary cirrhosis: Long-term outcomes. Am J Gastroenterol 2007; 102: 1244-50.
200. Lohse AW, zum Buschenfelde KH, Franz B, Kanzler S, Gerken G, Dienes HP. Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: Evidence for it being a hepatitic form of PBC in genetically susceptible individuals. Hepatology 1999; 29: 1078-84.